Coming later next month will be Veracyte, Critero, Chegg and CommScope. Overall, Cramer noted, health care, biotech and regular tech (think cloud computing) are all hot commodities at the moment, so investors should keep their eyes open.
House Democrats start probe into MS drug prices
'Biogen has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow.'
All eyes are on Pfizer in the months ahead.